Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through entities he is associated with, under a pre-arranged trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock indirectly through Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on October 1, 2024, for $35.16 per share.
• A total of 8,423 shares were sold.
• Kersten also reported the sale of 21,518 shares on October 2, 2024, at a weighted average price of $35.38.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by FCF IV on April 9, 2024.
• Kersten disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
• Following these transactions, Kersten indirectly owns 150,282 shares through FCF IV and 5,795,364 shares through ForDyne B.V.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, with no explicit positive or negative implications.

Risks

• The sales by a director could be perceived negatively by the market, although they were conducted under a pre-arranged trading plan.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. However, sales under pre-arranged trading plans are common and may not necessarily indicate a negative outlook.

Stakeholder Impact

• The stock sales could create short-term selling pressure on the stock.

Key Dates